Polycystic ovary syndrome: Clinical perspectives and management

Obstetrical and Gynecological Survey

Volumn 54, Issue 6, 1999, Pages 403-413

  Futterweit, Walter ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRASTERONE SULFATE; TESTOSTERONE;

ACNE; ALOPECIA; ANAMNESIS; FAMILY HISTORY; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MENSTRUATION DISORDER; OVARY POLYCYSTIC DISEASE; REVIEW; VIRILIZATION;

FEMALE; HUMANS; HYPERANDROGENISM; POLYCYSTIC OVARY SYNDROME; WOMEN'S HEALTH;

EID: 0033065195     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-199906000-00024     Document Type: Review

References (91)

1. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995; 16:322-353.
2. Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995;98(Suppl 1A):27S-32S.
3. Dunaif A. Hyperandrogenic anovulation (PCOS): A unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995; 98(Suppl 1A):33S-39S.
4. Azziz R, Dewailly D. Diagnosis, screening, and treatment of nonclassic 21-hydroxylase deficiency. In: Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Philadelphia: Lippincott-Raven Publishers, 1997, pp181-192.
5. Dahlgren E, Johansson S, Lindstedt G et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: A long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-513.
6. Chang RJ, Nakamura RM, Judd HL et al. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983;57:356-359.
7. Dunaif A, Segal KR, Futterweit W et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989:38:1165-1174.
8. Conway GS, Agrawal R, Betteridge DJ et al. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;37: 119-125.
9. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075-4079.
10. Wild RA, Grubb B, Hartz A et al. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 1990;54:255-259.
11. Nestler JE. Insulin and ovarian androgen excess. In: Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Philadelphia: Lippincott-Raven Publishers, 1997, pp 473-483.
12. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanisms and implications for pathogenesis. Endocr Rev 1997;18:774-800.
13. Fagan TC. The cardiovascular dysmetabolic syndrome. Am J Med 1998;105(Suppl 1A)77S-82S.
14. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83: 2694-2698.
15. Modan M, Harris MI, Halkin H. Evaluation of WHO and NDDG criteria for impaired glucose tolerance: Results from two national samples. Diabetes 1989;38:1630-1635.
16. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942-947.
17. Futterweit W. Pathophysiology of polycystic ovarian syndrome. In: Redmond GP, ed. Androgenic Disorders. New York: Raven Press, 1995, pp 77-166.
18. Zawadsky JK, Dunaif A. Polycystic Ovary Syndrome. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Cambridge, MA: Blackwell Scientific, 1992, pp 377-384.
19. Rosenfield RL, Lucky AW. Acne, hirsutism, and alopecia in adolescent girls. Endocrinol Metab Clin North Am 1993;22: 507-532.
20. Futterweit W. Clinical evaluation of androgen excess. In: Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Philadelphia: Lippincott-Raven Publishers, 1997, pp625-633.
21. Ferriman D, Purdie AW. The inheritance of PCO and possible relationship to premature balding. Clin Endocrinol (Oxf) 1979; 11:291-300.
22. Rosenfield RL. Pilosebaceous physiology in relation to hirsutism and acne. Clin Endocrinol Metab 1986;15:341-362.
23. Ehrmann DA, Rosenfield RL. An endocrinologic approach to the patient with hirsutism. J Clin Endocrinol Metab 1990;71: 1-5.
24. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
25. Hatch R, Rosenfield RL, Kim MH et al. Hirsutism implications, etiology, and management. Am J Obstet Gynecol 1981;140: 815-830.
26. Redmond GP. Clinical evaluation of the woman with an androgenic disorder. In: Redmond GP, ed. Androgenic Disorders. New York: Raven Press, 1995, pp 1-20.
27. Rosenfield RL, Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med 1995; 98(Suppl 1A):80S-88S.
28. Goldzieher JW, Green JA. The polycystic ovary: I. Clinical and histologic findings. J Clin Endocrinol Metab 1962;22:325-338.
29. Goldzieher JW. Polycystic ovarian disease. Fertil Steril 1981; 35:371-394.
30. Futterweit W. Clinical features of polycystic ovarian disease. Polycystic Ovarian Disease. New York: Springer-Verlag, 1984, pp83-95.
31. Gibson M. Reproductive health and polycystic ovary syndrome. Am J Med 1995;98(Suppl 1A):67S-75S.
32. Reingold SB, Rosenfield RL. The relationship of mild hirsutism or acne in women to androgens. Arch Dermatol 1987;123: 209-212.
33. Lucky A. Hormonal correlates of acne and hirsutism. Am J Med 1995;98(Suppl 1A):89S-94S.
34. Lucky AW, McGuire J, Rosenfield RL et al. Plasma androgens in women with acne vulgaris. J Invest Dermatol 1983;81:70-74.
35. Slayden SM, Azziz R. The role of androgen excess in acne. In: Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Philadelphia: Lippincott-Raven Publishers, 1997, pp131-140.
36. Marynick SP, Chakmakjian ZH, McCaffree DL et al. Androgen excess in cystic acne. N Engl J Med 1983;308:981-986.
37. Peserico A, Angeloni G, Bertoli P et al. Prevalence of polycystic ovaries in women with acne. Arch Dermatol Res 1989;281: 502-503.
38. Futterweit W, Dunaif A, Yeh HC et al. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 1988;19:831-836.
39. Barbieri RL. Effects of insulin on ovarian steroidogenesis. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic Ovary Syndrome. Cambridge, MA: Blackwell Scientific, 1992, pp 249-263.
40. Kissebah AH. Upper body obesity: Abnormalities in the metabolic profile and the androgenic/estrogenic balance. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic Ovary Syndrome. Cambridge, MA: Blackwell Scientific, 1992, pp 359-374.
41. Folsom AR, Kaye SA, Sellers TA et al. Body fat distribution and 5-year risk of death in older women. J Am Med Assoc 1993;269:483-487.
42. Futterweit W. Hyperprolactinemia and polycystic ovarian disease. Polycystic Ovarian Disease. New York: Springer-Verlag, 1984, pp 97-111.
43. Futterweit W, Krieger DT. Pituitary tumors associated with hyperprolactinemia and polycystic ovarian disease. Fertil Steril 1979;31:608-613.
44. Futterweit W. Laboratory diagnosis and differential diagnosis of polycystic ovarian disease. Polycystic Ovarian Disease. New York: Springer-Verlag, 1984, pp 113-135.
45. Pang S. The molecular and clinical spectrum of 3β-hydroxysteroid dehydrogenase deficiency disorder. Trends Endocrinol Metab 1998;9:82-86.
46. Karstaedt M, Sagel SS, Stanley RJ et al. Computed tomography of the adrenal gland. Radiology 1978;129:723-730.
47. Polson DW, Adams J, Wadsworth J et al. Polycystic ovaries - A common finding in normal women. Lancet 1988;1: 870-872.
48. Futterweit W, Scher J, Nunez AE et al. A case of bilateral dermoid cysts, insulin resistance, and polycystic ovarian disease: Association of ovarian tumors with polycystic ovaries with review of the literature. Mt Sinai J Med 1983;50:251-255.
49. Robinson S, Kiddy D, Gelding SV et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 1993;39:351-355.
50. Futterweit W. An endocrine approach to obesity. In: Simopoulos AP, Vanltallie TB, Gullo SP, Futterweit W, eds. Obesity: New Directions in Assessment and Management. New York: Charles Press, 1994, pp 96-121.
51. Kiddy DS, Hamilton-Fairley D, Bush A et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:105-111.
52. Pasquali R, Antenucci D, Casimirri F et al. Clinical and hormonal characteristics of obese and amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989;68:173-189.
53. Holte J, Bergh T, Berne C et al. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995;80:2586-2593.
54. Jakubowicz DJ, Nestler JE. 17α-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1997;82:556-560.
55. Andersen P, Seljeflot I, Abdelnoor M et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995;44:611-616.
56. Azziz R, Gay F. The treatment of hyperandrogenism with oral contraceptives. Semin Reprod Endocrinol 1989;7:246-254.
57. Burkman RT. The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 1995;98(Suppl 1A): 130S-136S.
58. Rittmaster RS. Medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab 1995;80:2559-2563.
59. Godsland IF, Walton C, Felton C et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992;74:64-70.
60. Cumming DC, Yang JC, Rebar RW et al. Treatment of hirsutism with spironolactone. J Am Med Assoc 1982;247:1295-1298.
61. Barth JH, Cherry CA, Wojnarowska F et al. Spironolactone is an effective and well tolerated systemic antiandrogen therapy for hirsute women. J Clin Endocrinol Metab 1989;68:966-970.
62. Falsetti L, Galbignani E. Long-term treatment with the combination ethylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception 1990;42:611-619.
63. Fruzetti F. Treatment of hirsutism. Antiandrogen and 5a-reductase inhibitor therapy. In: Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Philadelphia: Lippincott-Raven Publishers, 1997, pp 787-797.
64. O'Brien RC, Cooper ME, Murray RM et al. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism. J Clin Endocrinol Metab 1991;72:1008-1013.
65. Rushton HD, Ramsey ID. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinylestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol (Oxf) 1992;36:421-427.
66. Couzinet B, Pholsena M, Young J et al. The impact of a pure antiandrogen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin Endocrinol (Oxf) 1993;39: 157-162.
67. Fruzzetti F, De Lorenzo D, Ricci C et al. Clinical and endocrine effects of flutamide in hyperandrogenic women. Fertil Steril 1993;60:806-813.
68. Pucci E, Genazzani AD, Monzani F et al. Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Gynecol Endocrinol 1995;9:221-228.
69. Wysowski DK, Freiman JP, Tourtelot JB et al. Fatal and non-fatal hepatotoxicity associated with flutamide. Ann Intern Med 1993;118:860-864.
70. Golditch IM, Price VH. Treatment of hirsutism with cimetidine. Obstet Gynecol 1990;75:911-913.
71. Gokman O, Senoz S, Gulekli B et al. Comparison of four different treatment regimens in hirsutism related to polycystic ovary syndrome. Gynecol Endocrinol 1996;10:249-255.
72. Isik AZ, Gokmen O, Zeyneloglu HB et al. Low dose ketoconazole is an effective and safe alternative in the treatment of hirsutism. Aust N Z J Obstet Gynaecol 1996;36:487-489.
73. Rittmaster RS. 5-Alpha-reductase inhibitors. J Androl 1997; 18:582-587.
74. Wong IL, Morris RS, Chang L et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995;80:233-238.
75. Ciotta L, Cianci A, Calogero AE et al. Clinical and endocrine effects of finasteride, a 5a-reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril 1995;64:299-306.
76. Velazquez EM, Mendoza S, Hamer T et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-654.
77. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome. N Engl J Med 1996;335:617-623.
78. Diamanti-Kandarakis E, Kouli C, Tsianateli T et al. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998; 138:269-274.
79. Nestler JE, Jakubowicz DJ, Evans WS et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-1880.
80. Ehrmann DA, Cavaghan MK, Imperial J et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524-530.
81. Mantzoros CS, Dunaif A, Flier JS. Leptin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82: 1687-1691.
82. Dunaif A, Scott D, Finegood D et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3299-3306.
83. Ehrmann DA, Schneider DJ, Sobel BE et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary secretion. J Clin Endocrinol Metab 1997;82:2108-2116.
84. Carmina E, Lobo RA. Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism. Obstet Gynecol 1991;78:845-849.
85. Steinberger E, Rodriguez-Rigau LJ, Petak SM et al. Glucocorticoid therapy in hyperandrogenism. Baillieres Clin Obstet Gynaecol 1990;4:457-471.
86. McKenna TJ, Cunningham SK. Adrenal androgen production in polycystic ovary syndrome. Eur J Endocrinol 1995;133: 383-389.
87. Lemay A, Faure N. Sequential estrogen progestin addition to gonadotropin releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism. J Clin Endocrinol Metab 1994;79:1716-1722.
88. Rittmaster RS. Gonadotropin-releasing hormone (GnRH) agonists and estrogen/progestin replacement for the treatment of hirsutism: Evaluating the results [Editorial]. J Clin Endocrinol Metab 1995;80:3403-3405.
89. Steingold KA, Lobo RA, Judd HL et al. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease. J Clin Endocrinol Metab 1986;62:1048-1051.
90. Buvat J, Buvat-Herbaut M, Marcolin G et al. A double-blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome. J Clin Endocrinol Metab 1986;63:119-124.
91. Polson DW, Mason HD, Franks S. Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome. Clin Endocrinol (Oxf) 1987;26:197-203.